{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T12:34:15Z","timestamp":1761568455857,"version":"build-2065373602"},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1016\/j.clgc.2012.11.003","type":"journal-article","created":{"date-parts":[[2012,12,22]],"date-time":"2012-12-22T02:31:26Z","timestamp":1356143486000},"page":"78-84","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Safety and Efficacy of Maintenance Therapy With a Nonspecific Cytochrome P17 Inhibitor (CYP17i) After Response\/Stabilization to Docetaxel in Metastatic Castration-Resistant Prostate Cancer"],"prefix":"10.1016","volume":"11","author":[{"given":"Ignacio","family":"Gil-Bazo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Estefan\u00eda","family":"Ar\u00e9valo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ainhoa","family":"Castillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda E.","family":"Zudaire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar E.","family":"Carranza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan P.","family":"Fusco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Casta\u00f1\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00edctor","family":"Collado-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In\u00e9s","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Gil-Aldea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2012.11.003_bib1","first-page":"10","article-title":"Cancer statistics, 2012","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clgc.2012.11.003_bib2","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","article-title":"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","volume":"351","author":"Petrylak","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2012.11.003_bib3","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2012.11.003_bib4","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S1470-2045(03)01138-0","article-title":"Prostate cancer: a dynamic illness with shifting targets","volume":"4","author":"Shaffer","year":"2003","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2012.11.003_bib5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11154-008-9102-4","article-title":"Androgen synthesis in adrenarche","volume":"10","author":"Miller","year":"2009","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.clgc.2012.11.003_bib6","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0022-5347(17)49464-X","article-title":"Ketoconazole therapy in advanced prostatic cancer","volume":"132","author":"Trachtenberg","year":"1984","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2012.11.003_bib7","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/pros.21447","article-title":"Contemporary experience with ketoconazole in patients with metastatic castration-resistant prostate cancer: clinical factors associated with PSA response and disease progression","volume":"72","author":"Keizman","year":"2012","journal-title":"Prostate"},{"key":"10.1016\/j.clgc.2012.11.003_bib8","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1002\/cncr.22085","article-title":"Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer","volume":"107","author":"Nakabayashi","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2012.11.003_bib9","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1464-410X.2010.09825.x","article-title":"Low dose of ketoconazole in patients with prostate adenocarcinoma resistant to pharmacological castration","volume":"108","author":"Procopio","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2012.11.003_bib10","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1111\/j.1464-410X.2009.08971.x","article-title":"Activity of ketoconazole after taxane-based chemotherapy in castration-resistant prostate cancer","volume":"105","author":"Nakabayashi","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2012.11.003_bib11","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2012.11.003_bib12","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s10549-010-0860-9","article-title":"Maintenance treatment with pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study","volume":"122","author":"Alba","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clgc.2012.11.003_bib13","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1634\/theoncologist.2011-0249","article-title":"First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study","volume":"17","author":"D\u00edaz-Rubio","year":"2012","journal-title":"Oncologist"},{"key":"10.1016\/j.clgc.2012.11.003_bib14","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1200\/JCO.2002.08.674","article-title":"Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma","volume":"20","author":"Hainsworth","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2012.11.003_bib15","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1470-2045(12)70063-3","volume":"13","author":"Paz-Ares","year":"2012","journal-title":"Lancet Oncol"},{"issue":"suppl 1","key":"10.1016\/j.clgc.2012.11.003_bib16","first-page":"S3","article-title":"Androgen deprivation therapy in the treatment of advanced prostate cancer","volume":"9","author":"Perlmutter","year":"2007","journal-title":"Rev Urol"},{"author":"Eigl","key":"10.1016\/j.clgc.2012.11.003_bib17"},{"author":"Emmenegger","key":"10.1016\/j.clgc.2012.11.003_bib18"},{"key":"10.1016\/j.clgc.2012.11.003_bib19","doi-asserted-by":"crossref","first-page":"460","DOI":"10.3816\/CGC.2007.n.037","article-title":"Randomized, double-blind, placebo-controlled phase II trial of maintenance sunitinib versus placebo after chemotherapy for patients with advanced urothelial carcinoma: scientific rationale and study design","volume":"5","author":"Bradley","year":"2007","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2012.11.003_bib20","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1634\/theoncologist.12-4-451","article-title":"Sequential, alternating, and maintenance\/consolidation chemotherapy in advanced non-small cell lung cancer: a review of the literature","volume":"12","author":"Grossi","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.clgc.2012.11.003_bib21","first-page":"176","article-title":"Rationale for maintenance or consolidation therapy in ovarian cancer","volume":"1","author":"Markman","year":"2003","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.clgc.2012.11.003_bib22","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group","volume":"26","author":"Scher","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2012.11.003_bib23","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1471-2407-10-85","volume":"10","author":"Paz-Ares","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clgc.2012.11.003_bib24","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1159\/000109714","article-title":"Docetaxel plus prednisone versus mitoxantrone plus prednisone for metastatic hormone-refractory prostate cancer in Chinese patients: experience of a single center","volume":"79","author":"Zhang","year":"2007","journal-title":"Urol Int"},{"key":"10.1016\/j.clgc.2012.11.003_bib25","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1200\/JCO.2005.12.187","article-title":"Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer","volume":"23","author":"Oudard","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2012.11.003_bib26","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1023\/A:1006169012544","article-title":"Maintenance treatment with medroxyprogesterone acetate in patients with advanced breast cancer responding to chemotherapy: results of a randomized trial. Essen Breast Cancer Study Group","volume":"55","author":"Kloke","year":"1999","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clgc.2012.11.003_bib27","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1159\/000086976","article-title":"Maintenance hormone therapy with letrozole after first-line chemotherapy for advanced breast cancer","volume":"68","author":"Bertelli","year":"2005","journal-title":"Oncology"},{"key":"10.1016\/j.clgc.2012.11.003_bib28","doi-asserted-by":"crossref","first-page":"100","DOI":"10.7150\/ijms.5.100","article-title":"Maintenance hormonal treatment improves progression free survival after a first line chemotherapy in patients with metastatic breast cancer","volume":"5","author":"Dufresne","year":"2008","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.clgc.2012.11.003_bib29","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1634\/theoncologist.2010-0257","article-title":"Approval summary: erlotinib maintenance therapy of advanced\/metastatic non-small cell lung cancer (NSCLC)","volume":"15","author":"Cohen","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.clgc.2012.11.003_bib30","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1634\/theoncologist.2010-0224","article-title":"Approval summary: pemetrexed maintenance therapy of advanced\/metastatic nonsquamous, non-small cell lung cancer (NSCLC)","volume":"15","author":"Cohen","year":"2010","journal-title":"Oncologist"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767312002364?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767312002364?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:22:15Z","timestamp":1761564135000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767312002364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["S1558767312002364"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2012.11.003","relation":{},"ISSN":["1558-7673"],"issn-type":[{"type":"print","value":"1558-7673"}],"subject":[],"published":{"date-parts":[[2013,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and Efficacy of Maintenance Therapy With a Nonspecific Cytochrome P17 Inhibitor (CYP17i) After Response\/Stabilization to Docetaxel in Metastatic Castration-Resistant Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2012.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}